Description
Daonil 5mg represents an anti-diabetic pharmaceutical which exists as tablets under manufacturing by Emcure Pharmaceuticals Ltd. Medical practitioners administer Daonil 5mg to control blood glucose levels within NIDDM patients who have Non-Insulin Dependent Diabetes Mellitus. Glibenclamide regulates blood glucose through medication use to stop nerve problems and kidney problems and eye problems from developing.
Method of Action
Glibenclamide comprises the active ingredient found in Daonil 5mg tablets which belongs to a sulfonylurea pill class. Through its mechanism it activates pancreatic insulin production which normally serves to decrease blood glucose levels naturally. Using Daonil effectively requires patients to combine their medication with both balanced eating habits and regular physical activity. Daonil 5mg functions either independently or alongside insulin-dosing or other oral antidiabetic pills to enhance blood sugar regulation.
Key Features
Active Ingredient: Glibenclamide 5mg
Dosage Form: Tablet
Indication: Type 2 Diabetes Mellitus (NIDDM)
Benefits of Daonil 5mg
- Ensures there is stable blood sugar levels to avoid instances where a person feels extremely low and tired.
- Helps overcome the chances of having developing condition such as retinopathy, neuropathy, and kidney issue.
- Helps to stimulate the production of insulin in the pancreas.
- Can be combined with other diabetic pills and even insulin for getting a better effect.
Possible Side Effects
Some individuals may experience:
- Hypoglycemia (low blood sugar)
- Nausea
- Dizziness
- Weight gain
- Digestive discomfort
Conclusion
Daonil 5mg is an effective pill to control the increased levels of blood sugar in people with Type 2 diabetes and decrease the risk of developing chronic complications. However, they should be taken with a doctor’s advice and prescription, and accompanied by correct diet and exercise. Before using it, make sure to seek advice from your doctor to first know if it is right for you.
Reviews
There are no reviews yet.